{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:12:24Z","timestamp":1790745144503,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,5]],"date-time":"2015-01-05T00:00:00Z","timestamp":1420416000000},"content-version":"vor","delay-in-days":310,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jbo.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,15]],"date-time":"2014-01-15T04:49:29Z","timestamp":1389761369000},"page":"25-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["The anti-tumour effects of zoledronic acid"],"prefix":"10.1016","volume":"3","author":[{"given":"Jamal","family":"Zekri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mustafa","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jbo.2013.12.001_bib1","doi-asserted-by":"crossref","first-page":"8526","DOI":"10.1074\/jbc.C300511200","article-title":"Structural basis for bisphosphonate-mediated inhibition of isoprenoid biosynthesis","volume":"279","author":"Hosfield","year":"2004","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","article-title":"From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates","volume":"75","author":"Rogers","year":"2004","journal-title":"Calcif Tissue Int"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/A:1014418017382","article-title":"Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue","volume":"71","author":"Reinholz","year":"2002","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib6","first-page":"233","article-title":"Zoledronic acid inhibits proliferation of human fibrosarcoma cells with induction of apoptosis, and shows combined effects with other anticancer agents","volume":"24","author":"Koto","year":"2010","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib7","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.canlet.2008.09.026","article-title":"Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model","volume":"274","author":"Koto","year":"2009","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2106\/JBJS.H.01679","article-title":"Cytotoxic effect of zoledronic acid-loaded bone cement on giant cell tumor, multiple myeloma, and renal cell carcinoma cell lines","volume":"92","author":"Zwolak","year":"2010","journal-title":"J Bone Joint Surg Am"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3892\/or.2011.1152","article-title":"Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines","volume":"25","author":"Tamura","year":"2011","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/00365590802475904","article-title":"Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines","volume":"43","author":"Ullen","year":"2009","journal-title":"Scand J Urol Nephrol"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1600-0609.2007.00957.x","article-title":"Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells","volume":"79","author":"Koizumi","year":"2007","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1365-2184.2011.00745.x","article-title":"Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line","volume":"44","author":"Di Salvatore","year":"2011","journal-title":"Cell Prolif"},{"key":"10.1016\/j.jbo.2013.12.001_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/1477-3163.75723","article-title":"Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers","volume":"10","author":"Almubarak","year":"2011","journal-title":"J Carcinog"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib14","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1080\/02841860510029617","article-title":"Additive\/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid","volume":"44","author":"Ullen","year":"2005","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cellbi.2008.11.011","article-title":"Docetaxel\/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells","volume":"33","author":"Karabulut","year":"2009","journal-title":"Cell Biol Int"},{"issue":"8","key":"10.1016\/j.jbo.2013.12.001_bib16","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.jbo.2013.12.001_bib17","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.cellbi.2007.02.004","article-title":"Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study","volume":"31","author":"Ozturk","year":"2007","journal-title":"Cell Biol Int"},{"issue":"16","key":"10.1016\/j.jbo.2013.12.001_bib18","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jnci\/djn240","article-title":"Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer","volume":"100","author":"Ottewell","year":"2008","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib19","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/sj.bjc.6605579","article-title":"Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction","volume":"102","author":"Neville-Webbe","year":"2010","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib20","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence\u2010and schedule\u2010dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville\u2010Webbe","year":"2005","journal-title":"Int J Cancer"},{"issue":"suppl","key":"10.1016\/j.jbo.2013.12.001_bib21","volume":"31","author":"Charehbili","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.jbo.2013.12.001_bib22","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1158\/1078-0432.CCR-12-3235","article-title":"Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer\u2014a randomized biomarker pilot study","volume":"19","author":"Winter","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jbo.2013.12.001_bib23","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"issue":"15","key":"10.1016\/j.jbo.2013.12.001_bib24","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jbo.2013.12.001_bib25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jss.2008.01.031","article-title":"Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation","volume":"151","author":"Yamada","year":"2009","journal-title":"J Surg Res"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib27","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00784-009-0365-2","article-title":"Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro","volume":"15","author":"Ziebart","year":"2011","journal-title":"Clin Oral Investig"},{"issue":"14","key":"10.1016\/j.jbo.2013.12.001_bib29","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4161\/cbt.22274","article-title":"Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid","volume":"13","author":"Misso","year":"2012","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"10.1016\/j.jbo.2013.12.001_bib30","doi-asserted-by":"crossref","first-page":"e41065","DOI":"10.1371\/journal.pone.0041065","article-title":"Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells","volume":"7","author":"Tsai","year":"2012","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib31","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bone.2010.09.035","article-title":"Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase","volume":"48","author":"Stresing","year":"2011","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib32","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s00223-013-9720-z","article-title":"Effect of zoledronate on the responses of osteocytes to acute parathyroid hormone","volume":"92","author":"Kuroshima","year":"2013","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib33","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00774-009-0128-9","article-title":"Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice","volume":"28","author":"Kobayashi","year":"2010","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib35","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"Suppl. 3","key":"10.1016\/j.jbo.2013.12.001_bib36","doi-asserted-by":"crossref","first-page":"S733","DOI":"10.1002\/cncr.11148","article-title":"Role of stromal-derived cytokines and growth factors in bone metastasis","volume":"97","author":"David Roodman","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.21104","article-title":"Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect","volume":"104","author":"Corso","year":"2005","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.jbo.2013.12.001_bib38","first-page":"3890","article-title":"Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices","volume":"57","author":"Boissier","year":"1997","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<263::AID-IJC19>3.0.CO;2-T","article-title":"Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone","volume":"83","author":"Magnetto","year":"1999","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib40","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"van der Pluijm","year":"1996","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2174\/0929867033368529","article-title":"In vitro and in vivo antitumor effects of bisphosphonates","volume":"10","author":"Clezardin","year":"2003","journal-title":"Curr Med Chem"},{"issue":"10","key":"10.1016\/j.jbo.2013.12.001_bib42","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/sj.bjc.6600925","article-title":"New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects","volume":"88","author":"Denoyelle","year":"2003","journal-title":"Br J Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.jbo.2013.12.001_bib43","doi-asserted-by":"crossref","first-page":"S840","DOI":"10.1002\/cncr.11128","article-title":"Antitumor effects of bisphosphonates","volume":"97","author":"Green","year":"2003","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.jbo.2013.12.001_bib44","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","article-title":"Zoledronic acid inhibits visceral metastases in the 4T1\/luc mouse breast cancer model","volume":"10","author":"Hiraga","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.jbo.2013.12.001_bib45","first-page":"6015","article-title":"Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho","volume":"62","author":"Sawada","year":"2002","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jbo.2013.12.001_bib46","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1158\/0008-5472.CAN-05-0264","article-title":"Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity","volume":"65","author":"Clezardin","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib47","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1538-7836.2006.02259.x","article-title":"Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways","volume":"5","author":"Hasmim","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib48","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4049\/jimmunol.154.3.998","article-title":"V gamma 2V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer","volume":"154","author":"Bukowski","year":"1995","journal-title":"J Immunol"},{"issue":"4985","key":"10.1016\/j.jbo.2013.12.001_bib49","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1126\/science.1978758","article-title":"Recognition by human V gamma 9\/V delta 2 T cells of a GroEL homolog on Daudi Burkitt\u2032s lymphoma cells","volume":"250","author":"Fisch","year":"1990","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0167-5699(97)80010-2","article-title":"Sentinel function of broadly reactive human gamma delta T cells","volume":"18","author":"De Libero","year":"1997","journal-title":"Immunol Today"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib51","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib52","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib53","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib54","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/CJI.0b013e31802bff16","article-title":"Zoledronic acid has direct antiproliferative and antimetastatic effect on pancreatic carcinoma cells and acts as an antigen for delta2 gamma\/delta T cells","volume":"30","author":"Marten","year":"2007","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib55","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ijc.20987","article-title":"Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy","volume":"116","author":"Sato","year":"2005","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.jbo.2013.12.001_bib56","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3727\/096504010X12671222663638","article-title":"Zoledronate stimulates gamma delta T cells in prostate cancer patients","volume":"18","author":"Naoe","year":"2010","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib57","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib58","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00262-012-1368-4","article-title":"Zoledronic acid-induced expansion of gammadelta T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells","volume":"62","author":"Sugie","year":"2013","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2007.07.004","article-title":"The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages","volume":"66","author":"Allavena","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib60","first-page":"11","article-title":"Tumor-associated macrophages: effectors of angiogenesis and tumor progression","volume":"1796","author":"Coffelt","year":"2009","journal-title":"Biochim Biophys Acta."},{"issue":"11","key":"10.1016\/j.jbo.2013.12.001_bib61","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/0008-5472.CAN-07-0912","article-title":"Tumor-associated macrophages press the angiogenic switch in breast cancer","volume":"67","author":"Lin","year":"2007","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s13402-013-0156-2","article-title":"Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models","volume":"36","author":"Rogers","year":"2013","journal-title":"Cell Oncol (Dordr)"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib63","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.bcp.2006.09.031","article-title":"Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro","volume":"73","author":"Moreau","year":"2007","journal-title":"Biochem Pharmacol"},{"issue":"23","key":"10.1016\/j.jbo.2013.12.001_bib64","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.jbo.2013.12.001_bib65","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","article-title":"Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway","volume":"14","author":"Coscia","year":"2010","journal-title":"J Cell Mol Med"},{"issue":"12","key":"10.1016\/j.jbo.2013.12.001_bib66","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2013.12.001_bib67","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/02841860801964988","article-title":"Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer","volume":"47","author":"Kristensen","year":"2008","journal-title":"Acta Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib68","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib69","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib70","first-page":"1807","article-title":"Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer","volume":"30","author":"Rack","year":"2010","journal-title":"Anticancer Res"},{"issue":"S15","key":"10.1016\/j.jbo.2013.12.001_bib71","doi-asserted-by":"crossref","first-page":"S559","DOI":"10.1200\/jco.2008.26.15_suppl.559","article-title":"Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow","volume":"26","author":"Lin","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1089\/jir.2005.25.144","article-title":"Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients","volume":"25","author":"Vincenzi","year":"2005","journal-title":"J Interferon Cytokine Res"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib73","first-page":"1351","article-title":"Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours","volume":"15","author":"Santini","year":"2006","journal-title":"Oncol Rep"},{"issue":"15 Pt 1","key":"10.1016\/j.jbo.2013.12.001_bib74","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1158\/1078-0432.CCR-07-0551","article-title":"Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients","volume":"13","author":"Santini","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib75","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10549-010-1183-6","article-title":"Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance","volume":"124","author":"Zhao","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000087286","article-title":"Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients","volume":"69","author":"Ferretti","year":"2005","journal-title":"Oncology"},{"issue":"3","key":"10.1016\/j.jbo.2013.12.001_bib77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12032-008-9043-5","article-title":"Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases","volume":"25","author":"Tas","year":"2008","journal-title":"Med Oncol"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib78","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.jbo.2013.12.001_bib79","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CJI.0b013e318207ecfb","article-title":"Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadelta T cells: a phase I clinical study","volume":"34","author":"Sakamoto","year":"2011","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.jbo.2013.12.001_bib80","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.jbo.2013.12.001_bib81","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib82","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","article-title":"Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.jbo.2013.12.001_bib83","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jbo.2013.12.001_bib84","unstructured":"De Boer R., Bundred N., Eidtmann H., Llombart A., Neven P., von Minckwitz G., et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up. In: Proceedings of the 33rd annual San Antonio breast cancer symposium; 2010. p. 8\u201312."},{"key":"10.1016\/j.jbo.2013.12.001_bib85","doi-asserted-by":"crossref","unstructured":"Coleman R.E., Thorpe H.C., Cameron D., Dodwell D., Burkinshaw R., Keane M., et al. Adjuvant treatment with zoledronic acid in stage II\/III breast cancer. The AZURE trial (BIG 01\/04)(abstract S4\u2013S5). In: Proceedings from the San Antonio breast cancer symposium. San Antonio; 2010.","DOI":"10.1158\/0008-5472.SABCS10-S4-5"},{"issue":"6","key":"10.1016\/j.jbo.2013.12.001_bib86","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/1758834011420599","article-title":"Zoledronic acid in breast cancer: latest findings and interpretations","volume":"3","author":"Gnant","year":"2011","journal-title":"Ther Adv Med Oncol"},{"issue":"8","key":"10.1016\/j.jbo.2013.12.001_bib87","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1093\/annonc\/mds128","article-title":"Zoledronic acid in patients with stage IIIA\/B NSCLC: results of a randomized, phase III study","volume":"23","author":"Scagliotti","year":"2012","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jbo.2013.12.001_bib88","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/bjc.2012.210","article-title":"Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II\/III breast cancer","volume":"107","author":"Aft","year":"2012","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.jbo.2013.12.001_bib89","first-page":"281","article-title":"Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers","volume":"11","author":"Karim","year":"2013","journal-title":"Clin Adv Hematol Oncol"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137413000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:15:30Z","timestamp":1761941730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137413000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":89,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S2212137413000705"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2013.12.001","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The anti-tumour effects of zoledronic acid","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier GmbH.","name":"copyright","label":"Copyright"}]}}